Ipamorelin
99% Purity
99% Purity
Fast Shipping
Fast Shipping
Lab Tested
Lab Tested

Ipamorelin

★ ★ ★ ★ ★
4.5 (63 reviews)
Leave a Review

Premium Ipamorelin for research. Selective growth hormone secretagogue (pentapeptide). Minimal cortisol/prolactin effects. Often combined with CJC-1295. Third-party tested, 98% purity.

Key Research Properties:

Third-party tested for purity
Lyophilized powder form
Manufactured in USA
Fast, discreet shipping
Regular Price: $50.00
$50.00
SAVE 20%!
Special Discount Active - Limited Time!
SKU: VHL-IPA-001
Purity: 98% (HPLC Verified)
Form: Lyophilized Powder
Storage: Store at -20°C
Lot Number: IPA-2410-55: 2mg, 5mg
For Research Use Only.
All products are sold strictly for laboratory and research purposes. Products are not intended for human use or consumption of any kind.

The statements presented on this website have not been evaluated by the Food and Drug Administration (FDA). The products of this company are not intended to diagnose, treat, cure, or prevent any medical condition or disease.

What is Ipamorelin?

Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor agonist consisting of 5 amino acids. It is known for its high selectivity, stimulating GH release without significantly affecting cortisol or prolactin levels[1].

Ipamorelin Key Properties

  • Pentapeptide growth hormone secretagogue
  • Selective ghrelin receptor (GHS-R1a) agonist
  • Minimal effect on cortisol and prolactin[2]
  • Often combined with GHRH analogs for synergistic effect
  • Half-life: approximately 2 hours

Molecular Information

Molecular FormulaC38H49N9O5
Molecular Weight711.86 g/mol
Physical FormWhite lyophilized powder
Storage-20°C (powder); 2-8°C (reconstituted)
Purity≥98% (HPLC)

Mechanism of Action

Ipamorelin binds to and activates the ghrelin receptor (GHS-R1a) on pituitary somatotrophs, stimulating growth hormone release through a pathway distinct from GHRH[3].

Ghrelin Receptor Activation

Acts as a ghrelin mimetic, activating GHS-R1a via phospholipase C pathway, increasing intracellular calcium and stimulating GH release[4]

Selective Profile

Unlike many GHS, ipamorelin shows high selectivity for GH release without stimulating ACTH, cortisol, or prolactin secretion[2]

Synergy with GHRH Analogs

Ipamorelin is frequently studied in combination with GHRH analogs (CJC-1295, tesamorelin) due to complementary mechanisms:

  • Dual Pathway Activation: GHRH (cAMP) + GHS (PLC/calcium) = amplified GH pulse
  • Somatostatin Suppression: GHS can partially override somatostatin's inhibitory effects
  • Synergistic Effect: Combined administration produces 3-5x greater GH release than either alone[5]

Research Applications

Ipamorelin has been studied primarily in preclinical models and early-phase human research for GH stimulation, body composition, and recovery[6].

Primary Research Areas

Growth Hormone Dynamics

Studies investigate GH pulsatility, amplitude, and IGF-1 response in various populations and dosing regimens.

Body Composition

Research on lean mass preservation, fat loss, and metabolic effects in aging and catabolic states.

Preclinical Findings

  • GH Selectivity: Animal studies confirm selective GH stimulation without cortisol/prolactin elevation
  • Bone Health: Improvements in bone mineral density and bone turnover markers[7]
  • Gastric Motility: Less gastric emptying stimulation compared to GHRP-6 (reduced hunger effects)
  • Safety Profile: Well-tolerated in preclinical toxicology studies

Dosing Information

For Research Use Only

Not intended for human consumption. Research compound only.

Research Protocols

Typical Research Ranges: 200-300 μg per administration

Frequency: 1-3 times daily (often dosed before meals and/or bedtime)

Route: Subcutaneous injection

Combination: Often paired with CJC-1295 (1-2 mg weekly) for synergistic effect

Reconstitution

Product AmountBacteriostatic WaterConcentration
2 mg2 mL1 mg/mL (1000 μg/mL)
5 mg2 mL2.5 mg/mL (2500 μg/mL)

Storage & Stability

  • Lyophilized: -20°C, stable 24+ months
  • Reconstituted: 2-8°C, stable up to 14 days with bacteriostatic water
  • Handling: Sterile technique; protect from light

Safety & Side Effects

Ipamorelin has been studied in preclinical and limited human research with generally favorable tolerability[8].

Reported Effects in Research

  • Injection site reactions (mild, transient)
  • Increased appetite (less than GHRP-6, but possible)
  • Headache (occasional)
  • Flushing or warmth (transient)
  • Water retention (mild, GH-mediated)

Advantages Over Other GHS

Selective Profile: Unlike GHRP-2 or GHRP-6, ipamorelin does not significantly stimulate:

  • Cortisol (no ACTH stimulation)
  • Prolactin elevation
  • Excessive appetite/gastric motility

Theoretical Concerns

  • GH/IGF-1 related effects (similar to other GH secretagogues)
  • Unknown long-term safety profile (limited human data)
  • Potential for glucose metabolism effects (monitor in diabetes research)

Frequently Asked Questions

Ipamorelin: Highly selective for GH release; minimal effects on cortisol, prolactin, or appetite. GHRP-6: Potent GH stimulation but significant appetite increase and cortisol elevation. GHRP-2: Strong GH release with moderate cortisol/prolactin stimulation. Ipamorelin is preferred for "clean" GH stimulation without unwanted hormone effects.

The combination exploits synergistic mechanisms: CJC-1295 (GHRH analog) acts via cAMP pathway, while ipamorelin (GHS) acts via ghrelin receptors and calcium signaling. Together they produce significantly larger GH pulses (3-5x) than either compound alone, mimicking the body's natural coordination of GHRH and ghrelin signals. Additionally, GHS can partially override somatostatin inhibition, amplifying GHRH's effects.

Research protocols often administer ipamorelin on an empty stomach (before meals or before bed) to maximize GH response, as elevated glucose and insulin can blunt GH secretion. The 2-hour half-life allows for multiple daily dosing to create repeated GH pulses throughout the day, or single bedtime dosing to enhance nocturnal GH release. When combined with CJC-1295, ipamorelin is typically dosed 1-3 times daily while CJC-1295 is dosed 1-2 times weekly.

Clinical Trials & Research Studies

Ipamorelin has undergone preclinical evaluation and early-phase human trials, though it has not progressed to large-scale Phase 3 studies or regulatory approval.

Preclinical Studies: GH Selectivity

Animal Models: Studies in rats demonstrated:

  • Selective GH release without cortisol or prolactin elevation
  • Dose-dependent GH stimulation
  • Improvements in bone mineral density and trabecular architecture[7]
  • Favorable safety profile in toxicology studies
Phase 1 Human Studies

Early human research investigated:

  • Pharmacokinetics and pharmacodynamics
  • Dose-response relationships for GH stimulation
  • Confirmation of selective GH release profile
  • Safety and tolerability in healthy volunteers

Note: Ipamorelin remains an investigational compound without FDA approval for clinical use.

References & Citations

  1. Raun K, et al. "Ipamorelin, the first selective growth hormone secretagogue." Eur J Endocrinol. 1998;139(5):552-561.
  2. Gobburu JV, et al. "Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers." Pharm Res. 1999;16(9):1412-1416.
  3. Ankersen M, et al. "Growth hormone secretagogues: recent advances and new frontiers." Curr Opin Pharmacol. 2001;1(6):587-594.
  4. Smith RG, et al. "Peptidomimetic regulation of growth hormone secretion." Endocr Rev. 1997;18(5):621-645.
  5. Bowers CY, et al. "Synergistic activity of growth hormone (GH)-releasing peptide and GH-releasing hormone in vivo and in vitro." Metabolism. 1992;41(9 Suppl 2):5-8.
  6. Svensson J, et al. "Effects of growth hormone secretagogues on body composition." Growth Horm IGF Res. 2003;13(Suppl A):S10-15.
  7. Lall S, et al. "Growth hormone (GH)-independent stimulation of whole-body bone formation by ipamorelin, a selective GH secretagogue." J Endocrinol. 2002;175(3):729-737.
  8. Johansen PB, et al. "Ipamorelin, a new growth hormone-releasing peptide, induces longitudinal bone growth in rats." Growth Horm IGF Res. 1999;9(2):106-113.

3rd Party Testing & Quality Assurance

Quality Specifications

ParameterSpecificationMethod
Purity (HPLC)≥98.0%RP-HPLC-UV
IdentityMW 711.86 DaMass Spectrometry
Peptide Content≥95%AAA
Water Content≤8%Karl Fischer
Endotoxins≤5.0 EU/mgLAL assay

Certificates of Analysis available upon request with batch number.

Shopping Cart